AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) for use of its lung cancer drugs Tagrisso (osimertinib) and Imfinzi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback